+Compare
HSCS
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
4.81M

HSCS Heart Test Laboratories Forecast, Technical & Fundamental Analysis

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for HSCS with price predictions
08:00 PM EDT Sep 19, 2023

HSCS sees MACD Histogram just turned negative

HSCS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 19, 2023. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 8 instances where the indicator turned negative. In of the 8 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 18, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on HSCS as a result. In of 21 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

HSCS moved below its 50-day moving average on September 18, 2023 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HSCS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for HSCS entered a downward trend on August 22, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HSCS advanced for three days, in of 44 cases, the price rose further within the following month. The odds of a continued upward trend are .

HSCS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (38.911) is normal, around the industry mean (24.999). P/E Ratio (0.000) is within average values for comparable stocks, (80.409). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (6.287). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. HSCS's P/S Ratio (2000.000) is very high in comparison to the industry average of (59.144).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. HSCS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HSCS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Intuitive Surgical (NASDAQ:ISRG), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW), IQVIA Holdings (NYSE:IQV), Align Technology (NASDAQ:ALGN), Illumina (NASDAQ:ILMN), Exact Sciences Corp (NASDAQ:EXAS), Guardant Health (NASDAQ:GH).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 6.4B. The market cap for tickers in the group ranges from 27 to 3.82T. MKYSF holds the highest valuation in this group at 3.82T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was -2%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was -6%. AVGR experienced the highest price growth at 198%, while HSCS experienced the biggest fall at -54%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was 40%. For the same stocks of the Industry, the average monthly volume growth was -1% and the average quarterly volume growth was 85%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 71
Price Growth Rating: 59
SMR Rating: 83
Profit Risk Rating: 88
Seasonality Score: -22 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

HSCS is expected to report earnings to rise 23.53% to -20 cents per share on September 27

Heart Test Laboratories HSCS Stock Earnings Reports
Q3'23
Est.
$-0.21
Q2'23
Beat
by $0.01
Q1'23
Est.
$-0.16
Q4'22
Beat
by $0.06
Q3'22
Beat
by $0.02
The last earnings report on June 28 showed earnings per share of -17 cents, beating the estimate of -18 cents. With 298.05K shares outstanding, the current market capitalization sits at 4.81M.
A.I. Advisor
published General Information

General Information

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
N/A
Address
550 Reserve Street
Phone
+1 737 414-9213
Employees
12
Web
https://www.heartsciences.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BEAM25.230.73
+2.98%
Beam Therapeutics
DVA103.331.37
+1.34%
DaVita
KITT1.990.01
+0.51%
Nauticus Robotics
ARTNA45.30-0.54
-1.18%
Artesian Resources Corp
ENVB2.03-0.14
-6.45%
Enveric Biosciences

HSCS and

Correlation & Price change

A.I.dvisor indicates that over the last year, HSCS has been loosely correlated with GENE. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if HSCS jumps, then GENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HSCS
1D Price
Change %
HSCS100%
-13.41%
GENE - HSCS
37%
Loosely correlated
-0.59%
RSLS - HSCS
33%
Loosely correlated
+3.36%
HSDT - HSCS
32%
Poorly correlated
+1.54%
STSS - HSCS
26%
Poorly correlated
-15.73%
GMVDF - HSCS
23%
Poorly correlated
+17.12%
More

Groups containing HSCS

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HSCS
1D Price
Change %
HSCS100%
-13.41%
Medical Specialties
(undefined stocks)
5%
Poorly correlated
-0.82%
Medical Specialties
(undefined stocks)
4%
Poorly correlated
-0.82%